Research coaction
As a result of our publication in JPET with University of Bristol, contact was established with Prof. Amynah Pradhan at the University of Illinois, Chicago.
We have now initiated a collaboration with Prof. Pradhan who is a world leader in delta opioid neurobiology with a particular interest in migraine and with Prof. Eamonn Kelly (University of Bristol) our existing research partner and opioid expert with the intention of applying for NIH funding to synthesize and test a range of new DORA structures. The aim is to develop new compounds for treating migraine and other headaches.
Success could lead to new patents following up on our lead compound PN6047 and entry into the large international migraine/headache market.
Research coaction
As a result of our publication in JPET with University of Bristol, contact was established with Prof. Amynah Pradhan at the University of Illinois, Chicago.
We have now initiated a collaboration with Prof. Pradhan who is a world leader in delta opioid neurobiology with a particular interest in migraine and with Prof. Eamonn Kelly (University of Bristol) our existing research partner and opioid expert with the intention of applying for NIH funding to synthesize and test a range of new DORA structures. The aim is to develop new compounds for treating migraine and other headaches.
Success could lead to new patents following up on our lead compound PN6047 and entry into the large international migraine/headache market.
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
